Bone targeting potential of bisphosphonate-targeted liposomes - Preparation, characterization and hydroxyapatite binding in vitro

被引:104
作者
Hengst, V.
Oussoren, C.
Kissel, T.
Storm, G.
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands
[2] MCS Micro Carrier Syst GmbH, D-41460 Neuss, Germany
[3] Univ Marburg, Dept Pharmaceut & Biopharm, D-35032 Marburg, Germany
关键词
bisphosphonates; hydroxyapatite; liposomes; bone targeting;
D O I
10.1016/j.ijpharm.2006.11.024
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl-trisoxyethylenebisphosphonic acid (CHOL-TOE-BP), a new tailor-made BP derivative, was used as bone targeting moiety for liposomes. CHOL-TOE-BP-targeted liposomes were designed for the treatment of bone-related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL-TOE-BP-targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL-TOE-BP is useful as targeting device for liposomal drug delivery to bone. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:224 / 227
页数:4
相关论文
共 17 条
[1]
Liposomes - Opportunities in drug delivery [J].
Allen, TM .
DRUGS, 1997, 54 (Suppl 4) :8-14
[2]
Effect of 17 beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17 beta-estradiol serum kinetics and bone mass in rats [J].
Bauss, F ;
Esswein, A ;
Reiff, K ;
Sponer, G ;
MullerBeckmann, B .
CALCIFIED TISSUE INTERNATIONAL, 1996, 59 (03) :168-173
[3]
CROMMELIN DJ, 2002, BUSINESS BRIEFING PH
[4]
FLEISCH H, 1987, BONE, V8, pS23
[5]
Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
[6]
Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals [J].
Fujisawa, R ;
Wada, Y ;
Nodasaka, Y ;
Kuboki, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1996, 1292 (01) :53-60
[7]
Prostaglandin E2-bisphosphonate conjugates:: Potential agents for treatment of osteoporosis [J].
Gil, L ;
Han, YX ;
Opas, EE ;
Rodan, GA ;
Ruel, R ;
Seedor, JG ;
Tyler, PC ;
Young, RN .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (05) :901-919
[8]
INVITRO AND INVIVO ANTICALCIFICATION EFFECTS OF NOVEL BISHYDROXYIMINOPHOSPHONATES [J].
GOLOMB, G ;
SCHLOSSMAN, A ;
EITAN, Y ;
SAADEH, H ;
VANGELDER, JM ;
BREUER, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (10) :1004-1007
[9]
Synthesis and in vitro characterization of a tissue-selective fullerene:: Vectoring C60(OH)16AMBP to mineralized bone [J].
Gonzalez, KA ;
Wilson, LJ ;
Wu, WJ ;
Nancollas, GH .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (06) :1991-1997
[10]
GREB W, 2005, Patent No. 2005070952